Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

and its antibody asset Mim8, with the Phase III FRONTIER2 trial (NCT05053139) in haemophilia A completing earlier this year. Novo Nordisk has not yet published data from the study. Novo Nordisk is ...

Under the program Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline ... evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks ...

From Novo Nordisk's haemophilia portfolio, there are two oral presentations of note: first on the efficacy and safety results of an interim analysis from FRONTIER4, a phase 3 open-label, multi-centre ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its next-generation subcutaneous obesity candidate, CagriSema. Per the data ...